Futura Medical Share Discussion Threads

[mikethebike4] 02/7/2019 10:19

large trade in the states (famdf)

[j777j] 02/7/2019 08:34

The markets that Futura's ED and topical pain gels are targeting, are in excess of $12 billion pa. If they only get a small market share with 15% royalties,the numbers are massive. On top of that the previous broker had factored in a total of $90 million in upfront and milestone payments for the med gel.

[jaws6] 02/7/2019 08:12

seen this today hxxps://www.pro activeinvestors.co.uk/companies/stocktube/13946/futura-medical-plc---elevator-pitch-13946.html

[j777j] 01/7/2019 12:41

The game changer is that the TPR pain gels penetrate up to 10 times faster that currently available drugs. This means not only do they work much faster but should enable the application to be cut from say 4xday to 2x day.

[rrr] 01/7/2019 12:19

J777J 'I agree and it is actually twice the size of the ED market.' I'm not too surprised by that. Arthritis of the knee, say, not bad enough for an op, or maybe the patient too unfit for surgery, but very debilitating and painful. Lots of potentially very unpleasant side effects, some very serious, from oral NSAIDs. Try morphine or similar instead? again side effects are marked and of course they're addictive. So an effective topical NSAID such as TPR100, with reduced risk of systemic side effects, will be a valuable and welcome addition to the therapeutic armoury.

[j777j] 01/7/2019 12:11

That was on top of $75 million paid upfront after only a phase 2 study. "Lilly agreed to pay Icos, a biotechnology start-up company that owns the rights to the drug, an up-front fee of $75 million. Analysts said that amount was extremely high for a drug that had not yet entered the final, and most important, phase of clinical trials. In another unusual arrangement, the two companies will share the marketing and sales of the drug in North America and in Europe and split the profits 50-50."

[j777j] 01/7/2019 10:58

I agree and it is actually twice the size of the ED market. Liberum did not even include it in their last report. Topical Pain Relief Market to Reach $13.27 Bn, Globally, by 2025 Increase in geriatric population, rise in prevalence of arthritis, high demand from athletes, and lesser side effects as compared to conventional oral medicines facilitate the growth in the global topical pain relief industry. Non-opioids segment is likely to be lucrative from 2018 to 2025. Over-the-counter pain relief segment to lead in terms of revenue and growth by 2025. E-commerce segment to register the highest growth rate by 2025. Asia-Pacific to grow the fastest during the forecast period

[rrr] 01/7/2019 10:20

Don't forget TPR100: TPR100 - Topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism Marketing authorisation application by UK commercialisation partner, Thornton & Ross (a subsidiary of STADA AG) submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in July 2018. Ongoing commercial discussions with several potential distribution partners for other territories. Any further licensing deals are expected to be after UK regulatory approval. TPR100 - Post year end Supporting Thornton & Ross on responses to initial MHRA feedback received in February 2019. hTTps://www.futuramedical.com/content/news/archive19/100419.asp

[tiananmen] 01/7/2019 09:57

I meant over the next day or two.

[j777j] 01/7/2019 09:35

I am particularly interested in the 56p level,where a lot of investors bought shares.

[tiananmen] 01/7/2019 09:31

44p target next

[j777j] 01/7/2019 08:26

Huge and growing marketplace. Where viagra at launch became the fastest prescription product ever launched. Med2005 works in 5 to 10 mins v up to one hour. Global Erectile Dysfunction Drugs Market Will Reach USD 7.10 Billion by 2024: Zion Market Research According to the report, global erectile dysfunction drugs market was valued at approximately USD 4.82 billion in 2017 and is expected to generate revenue of around USD 7.10 billion by end of 2024, growing at a CAGR of around 5.70% between 2018 and 2024. Inetresting to note how much larger the market is (double the size,) according to independent research is,compared to the Liberum forecast where the see 140p as level if trials are complete success. So that number could turn out to be conservative.

[glavey] 01/7/2019 08:04

No matter how much medication is applied at some point it will loose its effectiveness.

[j777j] 01/7/2019 07:42

Interestingly the share price is still 60% below 2016 levels and yet they are within 12 weeks of phase 3 results.

[swiftnick] 28/6/2019 19:19

From 7p to 35p in eight months, and now half way to being a ten bagger.

[ih_116147] 28/6/2019 12:40

TPR100 approval stock will hit £1+ and with positive Phase readout of MED stock will explode to £3+ and its highly likely that results will be positive .. STRONG BUYYYYYYYYYYYYYYYYYYY love it

[j777j] 28/6/2019 11:18

When you factor in the Liberum report's numbers are significantly less than Futura's 2 independent reseach forecasts indicating around $1.4 peak sales. The upside they have, could well turn out to be a low ball number. Why on earth risk taking a pill when you can apply a much faster a safer topical gel? This is disruptive technology. When the Ceo is telling us that as of yesterday they have had huge interest,makes me think he is speaking to long suffering shareholders.

[cf456] 28/6/2019 10:10

That's a load of potential upside from the current price.